There are currently 245 ongoing clinical trials involving Metastatic Prostate Cancer
Of the 245 trials,112 trials are in Phase II
Furthermore, 38 trials are in Phase III
The global pharmaceutical industry is steadily developing new drugs for Metastatic Prostate Cancer, an Oncology condition. The largest number of ongoing clinical trials for Metastatic Prostate Cancer is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Metastatic Prostate Cancer-related drug trials.
National Cancer Institute US: The leading ongoing Metastatic Prostate Cancer related clinical trial sponsor
National Cancer Institute US is the top sponsor for Metastatic Prostate Cancer-related ongoing clinical trials.
University of Texas MD Anderson Cancer Center, University of Washington, Johnson & Johnson and Weill Cornell Medical College are among other notable clinical trial sponsors involved in Metastatic Prostate Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Metastatic Prostate Cancer
Enzalutamide (Xtandi), Abiraterone acetate (Zytiga) and Leuprolide acetate are among the key marketed drugs involving Metastatic Prostate Cancer.
Enzalutamide (Xtandi) is a phenylimidazolidine derivative, acts as anti-neoplastic agent. It functions via Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Antagonist mechanism of action. Enzalutamide is formulated as soft gelatin capsules and tablets for oral route of administration. Enzalutamide was first approved in 2012 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Astellas Pharma US Inc.
Abiraterone acetate (Zytiga) is an antineoplastic agent. It functions via Steroid 17 Alpha Hydroxylase/17,20 Lyase Inhibitor mechanism of action. Abiraterone acetate is formulated as tablets and film coated tablets for oral route of administration. Abiraterone acetate was first approved in 2011 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Janssen Biotech Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward